Shares of Evoke Pharma, Inc. (NASDAQ:EVOK) have earned an average recommendation of “Hold” from the eight brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $8.50.

A number of equities research analysts recently issued reports on the company. Seaport Global Securities restated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a research note on Friday, October 6th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Evoke Pharma in a report on Monday, September 18th. ValuEngine lowered Evoke Pharma from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research lowered Evoke Pharma from a “hold” rating to a “sell” rating in a report on Thursday, August 17th.

Evoke Pharma (NASDAQ EVOK) traded up 1.04% during trading on Wednesday, hitting $3.88. 285,189 shares of the company traded hands. Evoke Pharma has a 12-month low of $1.35 and a 12-month high of $4.55. The company’s market capitalization is $59.71 million. The stock has a 50 day moving average price of $3.14 and a 200 day moving average price of $2.74.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.15). During the same quarter last year, the company posted ($0.41) earnings per share. On average, equities analysts anticipate that Evoke Pharma will post ($0.87) earnings per share for the current year.

A hedge fund recently raised its stake in Evoke Pharma stock. Vanguard Group Inc. lifted its holdings in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 15.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 523,650 shares of the specialty pharmaceutical company’s stock after purchasing an additional 68,544 shares during the quarter. Vanguard Group Inc. owned 3.40% of Evoke Pharma worth $1,341,000 at the end of the most recent quarter. 12.88% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/11/evoke-pharma-inc-evok-receives-consensus-recommendation-of-hold-from-brokerages.html.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.